Circulating glucagon-like peptide-1 increases in response to short-term overfeeding in men

Nutrition and Metabolism

Volumn 10, Issue 1, 2013, Pages

  Wadden, Danny ^a   Cahill, Farrell ^a   Amini, Peyvand ^a   Randell, Edward ^a   Vasdev, Sudesh ^a   Yi, Yanqing ^a   Church, Jon ^a   Sun, Guang ^a  

^a MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

Author keywords

Diabetes; GLP 1; Nutritional regulation; Obesity; Overfeeding

Indexed keywords

GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ANTHROPOMETRY; ARTICLE; BODY COMPOSITION; BODY WEIGHT; CALORIE; CANADA; CONTROLLED STUDY; GLUCOSE METABOLISM; HUMAN; INSULIN RESISTANCE; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; OBESITY; OVERNUTRITION; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 84875873601     PISSN: None     EISSN: 17437075     Source Type: Journal    
DOI: 10.1186/1743-7075-10-33     Document Type: Article

References (50)

1. Role of gut hormones in obesity. Jayasena CN, Bloom SR, Endocrinol Metab Clin North Am 2008 37 769 787 xi 10.1016/j.ecl.2008.07.001 18775363
2. The physiology of glucagon-like peptide 1. Holst JJ, Physiol Rev 2007 87 1409 1439 10.1152/physrev.00034.2006 17928588
3. Secretion of the incretin hormones glucagon-like peptide-1 and gastric inhibitory polypeptide correlates with insulin secretion in normal man throughout the day. Orskov C, Wettergren A, Holst JJ, Scand J Gastroenterol 1996 31 665 670 10.3109/00365529609009147 8819215
4. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus. Vilsboll T, Krarup T, Sonne J, Madsbad S, Volund A, Juul AG, Holst JJ, J Clin Endocrinol Metab 2003 88 2706 2713 10.1210/jc.2002-021873 12788877
5. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. Deacon CF, Johnsen AH, Holst JJ, J Clin Endocrinol Metab 1995 80 952 957 10.1210/jc.80.3.952 7883856
6. Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine. Hansen L, Deacon CF, Orskov C, Holst JJ, Endocrinology 1999 140 5356 5363 10.1210/en.140.11.5356 10537167
7. Suppression of glucagon secretion is lower after oral glucose administration than during intravenous glucose administration in human subjects. Meier JJ, Deacon CF, Schmidt WE, Holst JJ, Nauck MA, Diabetologia 2007 50 806 813 10.1007/s00125-007-0598-z 17334652
8. The impact of diabetic autonomic neuropathy on the incretin effect. Kazakos KA, Sarafidis PA, Yovos JG, Med Sci Monit 2008 14 R213 CR220 18376350
9. Effect of truncated glucagon-like peptide-1 [proglucagon-(78-107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach. Orskov C, Holst JJ, Nielsen OV, Endocrinology 1988 123 2009 2013 10.1210/endo-123-4- 2009 2901341
10. Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients. Creutzfeldt WO, Kleine N, Willms B, Orskov C, Holst JJ, Nauck MA, Diabetes Care 1996 19 580 586 10.2337/diacare.19.6.580 8725855
11. Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, inhibits glucagon secretion via somatostatin (receptor subtype 2) in the perfused rat pancreas. de Heer J, Rasmussen C, Coy DH, Holst JJ, Diabetologia 2008 51 2263 2270 10.1007/s00125-008-1149-y 18795252
12. Central pre-proglucagon derived peptides: opportunities for treatment of obesity. Larsen PJ, Vrang N, Tang-Christensen M, Curr Pharm Des 2003 9 1373 1382 10.2174/1381612033454775 12769729
13. Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men. Naslund E, Barkeling B, King N, Gutniak M, Blundell JE, Holst JJ, Rossner S, Hellstrom PM, Int J Obes Relat Metab Disord 1999 23 304 311 10.1038/sj.ijo.0800818 10193877
14. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. Flint A, Raben A, Astrup A, Holst JJ, J Clin Invest 1998 101 515 520 10.1172/JCI990 9449682
15. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Nauck MA, Niedereichholz U, Ettler R, Holst JJ, Orskov C, Ritzel R, Schmiegel WH, Am J Physiol 1997 273 981 E988 9374685
16. Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man. Wettergren A, Schjoldager B, Mortensen PE, Myhre J, Christiansen J, Holst JJ, Dig Dis Sci 1993 38 665 673 10.1007/BF01316798 8462365
17. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Nauck M, Stockmann F, Ebert R, Creutzfeldt W, Diabetologia 1986 29 46 52 10.1007/BF02427280 3514343
18. Therapy of type 2 diabetes mellitus based on the actions of glucagon-like peptide-1. Holst JJ, Diabetes Metab Res Rev 2002 18 430 441 10.1002/dmrr.328 12469357
19. Glucagon-like peptide-1 synthetic analogs: new therapeutic agents for use in the treatment of diabetes mellitus. Holz GG, Chepurny OG, Curr Med Chem 2003 10 2471 2483 10.2174/0929867033456648 14529486
20. Diurnal profile of pancreatic polypeptide, pancreatic glucagon, gut glucagon and insulin in human morbid obesity. Holst JJ, Schwartz TW, Lovgreen NA, Pedersen O, Beck-Nielsen H, Int J Obes 1983 7 529 538 6360922
21. Oral glutamine increases circulating glucagon-like peptide 1, glucagon, and insulin concentrations in lean, obese, and type 2 diabetic subjects. Greenfield JR, Farooqi IS, Keogh JM, Henning E, Habib AM, Blackwood A, Reimann F, Holst JJ, Gribble FM, Am J Clin Nutr 2009 89 106 113 19056578
22. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. Toft-Nielsen MB, Damholt MB, Madsbad S, Hilsted LM, Hughes TE, Michelsen BK, Holst JJ, J Clin Endocrinol Metab 2001 86 3717 3723 10.1210/jc.86.8.3717 11502801
23. A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. Newgard CB, An J, Bain JR, Muehlbauer MJ, Stevens RD, Lien LF, Haqq AM, Shah SH, Arlotto M, Slentz CA, Cell Metab 2009 9 311 326 10.1016/j.cmet.2009.02.002 19356713
24. Distal small bowel hormones: correlation with fasting antroduodenal motility and gastric emptying. Naslund E, Gryback P, Backman L, Jacobsson H, Holst JJ, Theodorsson E, Hellstrom PM, Dig Dis Sci 1998 43 945 952 10.1023/A:1018806129102 9590405
25. The role of postprandial releases of insulin and incretin hormones in meal-induced satiety - effect of obesity and weight reduction. Verdich C, Toubro S, Buemann B, Lysgard Madsen J, Juul Holst J, Astrup A, Int J Obes Relat Metab Disord 2001 25 1206 1214 10.1038/sj.ijo.0801655 11477506
26. A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans. Verdich C, Flint A, Gutzwiller JP, Naslund E, Beglinger C, Hellstrom PM, Long SJ, Morgan LM, Holst JJ, Astrup A, J Clin Endocrinol Metab 2001 86 4382 4389 10.1210/jc.86.9.4382 11549680
27. Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. Gutzwiller JP, Drewe J, Goke B, Schmidt H, Rohrer B, Lareida J, Beglinger C, Am J Physiol 1999 276 1541 R1544 10233049
28. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Zander M, Madsbad S, Madsen JL, Holst JJ, Lancet 2002 359 824 830 10.1016/S0140-6736(02)07952-7 11897280
29. Serum peptide YY in response to short-term overfeeding in young men. Cahill F, Shea JL, Randell E, Vasdev S, Sun G, Am J Clin Nutr 2011 93 741 747 10.3945/ajcn.110.003624 21289220
30. Adipose tissue lipolysis after long-term overfeeding in identical twins. Mauriege P, Despres JP, Marcotte M, Tremblay A, Nadeau A, Moorjani S, Lupien P, Dussault J, Fournier G, Theriault G, Int J Obes Relat Metab Disord 1992 16 219 225 1317832
31. Serum retinol-binding protein 4 concentrations in response to short-term overfeeding in normal-weight, overweight, and obese men. Shea J, Randell E, Vasdev S, Wang PP, Roebothan B, Sun G, Am J Clin Nutr 2007 86 1310 1315 17991640
32. Serum visfatin concentrations are positively correlated with serum triacylglycerols and down-regulated by overfeeding in healthy young men. Sun G, Bishop J, Khalili S, Vasdev S, Gill V, Pace D, Fitzpatrick D, Randell E, Xie YG, Zhang H, Am J Clin Nutr 2007 85 399 404 17284735
33. Impact of short-term high-fat feeding on glucose and insulin metabolism in young healthy men. Brons C, Jensen CB, Storgaard H, Hiscock NJ, White A, Appel JS, Jacobsen S, Nilsson E, Larsen CM, Astrup A, J Physiol 2009 587 2387 2397 10.1113/jphysiol.2009.169078 19332493
34. Effects of a hypercaloric diet on beta-cell responsivity in lean healthy men. Brands M, Swat M, Lammers NM, Sauerwein HP, Endert E, Ackermans MT, Verhoeven AJ, Serlie MJ, Clin Endocrinol (Oxf) 2012 78 2 217 225
35. Measurement of ad libitum food intake, physical activity, and sedentary time in response to overfeeding. He J, Votruba S, Pomeroy J, Bonfiglio S, Krakoff J, PLoS One 2012 7 36225 10.1371/journal.pone.0036225 22629311
36. Changes in the transcriptome of abdominal subcutaneous adipose tissue in response to short-term overfeeding in lean and obese men. Shea J, French CR, Bishop J, Martin G, Roebothan B, Pace D, Fitzpatrick D, Sun G, Am J Clin Nutr 2009 89 407 415 19056584
37. Assessment of total body fat percentage from regional spine and femur DXA measurements among Chinese women and men. Zhang TM, Xu H, Yuan ZM, Chen JX, Gong J, Wu QL, J Clin Densitom 2007 10 55 64 10.1016/j.jocd.2006.11.003 17289527
38. Comparison of multifrequency bioelectrical impedance analysis with dual-energy X-ray absorptiometry for assessment of percentage body fat in a large, healthy population. Sun G, French CR, Martin GR, Younghusband B, Green RC, Xie YG, Mathews M, Barron JR, Fitzpatrick DG, Gulliver W, Zhang H, Am J Clin Nutr 2005 81 74 78 15640463
39. Bray GA, Contemporary diagnosis and management of obesity. Handbooks in Health Care 2003
40. Serum acylated ghrelin concentrations in response to short-term overfeeding in normal weight, overweight, and obese men. Wadden D, Cahill F, Amini P, Randell E, Vasdev S, Yi Y, Zhang W, Sun G, PLoS One 2012 7 45748 10.1371/journal.pone.0045748 23029221
41. Glucagon-like peptide (GLP)-1 and leptin concentrations in obese patients with Type 2 diabetes mellitus. Mannucci E, Ognibene A, Cremasco F, Bardini G, Mencucci A, Pierazzuoli E, Ciani S, Fanelli A, Messeri G, Rotella CM, Diabet Med 2000 17 713 719 11110504
42. A paradox resolved: the postprandial model of insulin resistance explains why gynoid adiposity appears to be protective. McCarty MF, Med Hypotheses 2003 61 173 176 10.1016/S0306-9877(02)00238-4 12888298
43. Peripheral adiposity exhibits an independent dominant antiatherogenic effect in elderly women. Tanko LB, Bagger YZ, Alexandersen P, Larsen PJ, Christiansen C, Circulation 2003 107 1626 1631 10.1161/01.CIR.0000057974.74060. 68 12668497
44. Exenatide once weekly improved glycaemic control, cardiometabolic risk factors, and a composite index of an HbA1c<7%, without weight gain or hypoglycaemia, over 52 weeks. Bergenstal RM, Li Y, Booker Porter TK, Weaver C, Jenny Han M, Diabetes Obes Metab 2012 15 3 264 271 23078638
45. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Klonoff DC, Buse JB, Nielsen LL, Guan X, Bowlus CL, Holcombe JH, Wintle ME, Maggs DG, Curr Med Res Opin 2008 24 275 286 18053320
46. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Blonde L, Klein EJ, Han J, Zhang B, Mac SM, Poon TH, Taylor KL, Trautmann ME, Kim DD, Kendall DM, Diabetes Obes Metab 2006 8 436 447 10.1111/j.1463-1326.2006.00602.x 16776751
47. Multifactorial intervention in Type 2 diabetes: the promise of incretin-based therapies. Giorgino F, Leonardini A, Natalicchio A, Laviola L, J Endocrinol Invest 2011 34 69 77 21233599
48. Basal GLP-1 levels in morbidly obese patients following biliopancreatic diversion surgery. de Luis D, Pacheco D, Conde R, Primo D, Aller R, Izaola O, Ann Nutr Metab 2012 61 70 73 10.1159/000339378 22846622
49. Elevated circulating levels of an incretin hormone, glucagon-like peptide-1, are associated with metabolic components in high-risk patients with cardiovascular disease. Yamaoka-Tojo M, Tojo T, Takahira N, Matsunaga A, Aoyama N, Masuda T, Izumi T, Cardiovasc Diabetol 2010 9 17 10.1186/1475-2840-9-17 20470376
50. Analysis of glucagon-like peptide 1; what to measure? Heijboer AC, Frans A, Lomecky M, Blankenstein MA, Clin Chim Acta 2011 412 1191 1194 10.1016/j.cca.2011.03.010 21414305